Phase I/Ii Trial To Evaluate The Efficacy And Safety Of Nanoparticle Albumin-Bound Paclitaxel In Combination With Gemcitabine In Patients With Pancreatic Cancer And An Ecog Performance Status Of 2
JOURNAL OF CLINICAL ONCOLOGY(2019)
Abstract
PurposeGemcitabine plus nanoparticle albumin-bound (NAB) paclitaxel (GA) significantly improved survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and a Karnofsky performance status (PS) of 70% or greater. Because of the low number of patients with reduced PS, the efficacy of this regimen in fragile patients remains unclear. This study aimed to evaluate the efficacy and tolerability of different GA dosing regimens in patients with a poor PS.Patients and MethodsIn the phase I part of this study, patients were randomly assigned to one of the following four parallel GA treatment arms (six patients per arm): a biweekly schedule of NAB-paclitaxel (150 mg/m(2) [arm A] or 125 mg/m(2) [arm C]) plus gemcitabine 1,000 mg/m(2) or a standard schedule of 3 weeks on and 1 week off of NAB-paclitaxel (100 mg/m(2) [arm B] or 125 mg/m(2) [arm D]) plus gemcitabine 1,000 mg/m(2). The two regimens with the better tolerability profile on the basis of predefined criteria were evaluated in the phase II part of the study, the primary end point of which was 6-month actuarial survival.ResultsArms B and D were selected for the phase II part of the study. A total of 221 patients (111 patients in arm B and 110 patients in arm D) were enrolled. Baseline characteristics including median age (71 and 68 years in arms B and D, respectively), sex (51% and 55% men in arms B and D, respectively), and metastatic disease (88% and 84% in arms B and D, respectively) were comparable between arms. The most frequent grade 3 or 4 toxicities in arms B and D were anemia (12% and 7%, respectively), neutropenia (32% and 30%, respectively), thrombocytopenia (7% and 11%, respectively), asthenia (14% and 16%, respectively), and neurotoxicity (11% and 16%, respectively). In arms B and D, there were no significant differences in response rate (24% and 28%, respectively), median progression-free survival (5.7 and 6.7 months, respectively), and 6-month overall survival (63% and 69%, respectively).ConclusionNAB-paclitaxel administered at either 100 and 125 mg/m(2) in combination with gemcitabine on days 1, 8, and 15 every 28 days is well tolerated and results in acceptable safety and efficacy in patients with metastatic pancreatic ductal adenocarcinoma and a poor PS.
MoreTranslated text
Key words
pancreatic cancer,paclitaxel,gemcitabine,albumin-bound
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined